ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
A Study to Asses Effectiveness and Treatment Management of Oral Venetoclax Tablets + Subcutaneously Injected Azacitidine in Adult Participants Ineligible for Intensive Chemotherapy With de Novo Acute Myeloid Leukemia (AML) in Italy
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 150
- Registration Number
- NCT06058741
- Locations
- 🇮🇹
Azienda Ospedaliero Universitaria delle Marche /ID# 261822, Ancona, Italy
🇮🇹Ospedale San Martino /ID# 258981, Genoa, Genova, Italy
🇮🇹IRCCS Istituto Clinico Humanitas /ID# 259300, Rozzano, Lombardia, Italy
A Study to Evaluate Changes in Hair in Adult Participants Taking Oral Oriahnn Capsules With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
- Conditions
- Uterine Fibroids (UF)
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1600
- Registration Number
- NCT06058728
- Locations
- 🇺🇸
Dorsata /ID# 252675, Arlington, Virginia, United States
A Study to Compare the Bioavailability of Intravenously Infused Risankizumab Manufactured by Two Different Processes in Healthy Adults
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 48
- Registration Number
- NCT06054425
- Locations
- 🇺🇸
Anaheim Clinical Trials LLC /ID# 260740, Anaheim, California, United States
🇺🇸Clinical Pharmacology of Miami /ID# 260800, Miami, Florida, United States
🇺🇸Acpru /Id# 260864, Grayslake, Illinois, United States
A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382
- Conditions
- Human Immuno-deficiency Virus (HIV) Disease
- Interventions
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 163
- Registration Number
- NCT06032546
- Locations
- 🇺🇸
University of Alabama at Birmingham, 1917 Research Clinic /ID# 257549, Birmingham, Alabama, United States
🇺🇸Franco Felizarta, Md /Id# 256927, Bakersfield, California, United States
🇺🇸AHF Research Center /ID# 257025, Beverly Hills, California, United States
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)
- Conditions
- Generalized Anxiety Disorder (GAD)Bipolar Disorder (BPD)Healthy Volunteers
- Interventions
- Drug: Placebo for ABBV-932
- First Posted Date
- 2023-09-06
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 72
- Registration Number
- NCT06024239
- Locations
- 🇺🇸
Collaborative Neuroscience Research CNS /ID# 260270, Los Alamitos, California, United States
🇺🇸Acpru /Id# 255945, Grayslake, Illinois, United States
🇺🇸Hassman Research Institute Marlton Site /ID# 260271, Marlton, New Jersey, United States
An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Participants With Moderate to Severe Active Crohn's Disease (CD) in Japan
- Conditions
- Crohn's Disease
- First Posted Date
- 2023-09-05
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 240
- Registration Number
- NCT06023030
- Locations
- 🇯🇵
Itami City Hospital /ID# 276258, Itami, Hyogo, Japan
🇯🇵Aoyama Clinic /ID# 262658, Kobe-shi, Hyogo, Japan
🇯🇵Japanease Red Cross Society Himeji Hospital /ID# 275590, Himeji, Japan
A Study to Assess Adverse Events and Effectiveness of HAC 20L Injections in Adult Participants for the Treatment of Nasolabial Folds
- Conditions
- Nasolabial Folds
- Interventions
- Device: HAC 20LOther: No-Treatment Control
- First Posted Date
- 2023-08-31
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 61
- Registration Number
- NCT06018987
- Locations
- 🇩🇪
MediCorium Zentrum fuer Dermatologie und Aesthetik /ID# 231403, Oberursel, Hessen, Germany
🇩🇪Privatpraxis Dr. Hilton & Partner /ID# 231401, Duesseldorf, Nordrhein-Westfalen, Germany
🇩🇪Noahklinik GmbH /ID# 231917, Kassel, Germany
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1399
- Registration Number
- NCT06012240
- Locations
- 🇵🇷
Santa Cruz Behavioral (SCB) Research Center /ID# 259350, Bayamon, Puerto Rico
🇧🇬UMHAT Sveti Georgi /ID# 257548, Plovdiv, Bulgaria
🇺🇸Total Skin and Beauty Dermatology Center /ID# 259539, Birmingham, Alabama, United States
A Study to Assess Pharmacokinetics, Safety, and Tolerability of ABBV-903 in Healthy Japanese and Han Chinese Participants
- First Posted Date
- 2023-08-24
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 24
- Registration Number
- NCT06009237
- Locations
- 🇺🇸
Anaheim Clinical Trials LLC /ID# 257033, Anaheim, California, United States
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 110
- Registration Number
- NCT05995353
- Locations
- 🇫🇷
AP-HP - Hopital Necker /ID# 255608, Paris, France
🇵🇷Clinical Research Puerto Rico /ID# 266479, San Juan, Puerto Rico
🇫🇷CHU Toulouse - Hopital Paule de Viguier /ID# 255609, Toulouse, France